mdxhealth Data from the ProMPT study shows predictive value of GPS test

At EAU 2026, mdxhealth presented data from Oxford's ProMPT study, demonstrating that the GPS test successfully stratifies the risk of treatment failure across treatment cohorts. The results showed high six-year freedom-from-failure rates. Mdxhealth and Oxford will continue their collaboration through the recently initiated ProtecT-GPS study, with management expecting data read-outs in 2026/2027. We believe these data could support future market share gains for GPS mdx and could help expand the market by further demonstrating the utility of such tests. $ 6 TP and BUY.